Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase 2 2

Status

Completed 3Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 7Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 6Gynecologic 1

Conditions

Ovarian Neoplasms 14Fallopian Tube Neoplasms 12Breast Neoplasms 8Prostatic Neoplasms 7Neoplasms 7Carcinoma, Ovarian Epithelial 6Endometrial Neoplasms 5Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Metastatic Castration Resistant Prostate Cancer 2Lung Neoplasms 2Leiomyosarcoma 2Carcinoma, Transitional Cell 2Urethral Neoplasms 1Ureteral Neoplasms 1Solid Tumor, Unspecified, Adult 1Sarcoma 1Prostate Cancer Metastatic 1Primary Myelofibrosis 1Pathologic Complete Response 1Myeloproliferative Disorders 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × Neoplasms × rucaparib × Clear all
NCT03899155 2026-05-27

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT03768063 2026-04-28

IMbrella B

Hoffmann-La Roche

Phase 3 Active not recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

NCT03522246 2025-06-24

ATHENA

pharmaand GmbH

Phase 3 Active not recruiting
1,097 enrolled 26 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

NCT02740712 2023-06-09

DDI

pharmaand GmbH

Phase 1 Completed
17 enrolled
Tumor-Agnostic

Neoplasms

NCT03521037 2023-06-09

Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor

pharmaand GmbH

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasms

NCT03954366 2023-06-08

Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

pharmaand GmbH

Phase 1 Completed
36 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡